scholarly article | Q13442814 |
P356 | DOI | 10.2967/JNUMED.108.058396 |
P8608 | Fatcat ID | release_u3rdgrrhwbbndnfadxnnr6wdbm |
P698 | PubMed publication ID | 19289420 |
P5875 | ResearchGate publication ID | 24203810 |
P50 | author | Martin Walter | Q42847024 |
P2093 | author name string | Rebecca A Dumont | |
Michael W Yeh | |||
Matthias R Benz | |||
Vatche G Agopian | |||
Martin S Auerbach | |||
Johannes G Czernin | |||
Farzin Imani | |||
Chi Kien Lai | |||
Firoozeh Imani | |||
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | phaeochromocytoma | Q536269 |
P304 | page(s) | 513-519 | |
P577 | publication date | 2009-03-16 | |
P1433 | published in | The Journal of Nuclear Medicine | Q7743608 |
P1476 | title | 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas. | |
P478 | volume | 50 |
Q38082417 | 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type |
Q64988101 | Adrenal tracer uptake by 18F-FDOPA PET/CT in patients with pheochromocytoma and controls. |
Q35009855 | Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma |
Q37482780 | Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma |
Q58005428 | Diagnostic accuracy of [18F]DOPA PET and PET/CT in patients with neuroendocrine tumors: a meta-analysis |
Q37987448 | Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis |
Q36467722 | EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma |
Q33744014 | Fluorine-18-fluorodihydroxyphenylalanine Positron-emission Tomography Scans of Neuroendocrine Tumors (Carcinoids and Pheochromocytomas). |
Q51510849 | Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine. |
Q37986065 | Imaging with non-FDG PET tracers: outlook for current clinical applications |
Q37962361 | Malignant pheochromocytomas and paragangliomas: a diagnostic challenge |
Q37730951 | Molecular imaging of neuroendocrine tumors |
Q33897851 | Novel use of F-DOPA PET/CT imaging in a child with paraganglioma/pheochromocytoma syndrome |
Q41839681 | Nuclear medicine imaging in the evaluation of endocrine hypertension |
Q35972320 | Pheochromocytoma and paraganglioma: current functional and future molecular imaging |
Q34410500 | Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment |
Q34145968 | Pheochromocytoma in a Twelve-Year-Old Girl with SDHB-Related Hereditary Paraganglioma-Pheochromocytoma Syndrome. |
Q37618594 | Progress and challenges in neuroendocrine and neural crest tumours: molecular imaging and therapy. |
Q34266352 | SDHB-Associated Paraganglioma in a Pediatric Patient and Literature Review on Hereditary Pheochromocytoma-Paraganglioma Syndromes. |
Q38348673 | The incremental benefit of functional imaging in pheochromocytoma/paraganglioma: a systematic review |